Affimed (AFMD) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Affimed (NASDAQ:AFMD) from a buy rating to a hold rating in a research report report published on Wednesday.

According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “

Shares of NASDAQ:AFMD opened at $1.85 on Wednesday. Affimed has a fifty-two week low of $1.15 and a fifty-two week high of $2.85. The company has a market cap of $115.42, a P/E ratio of -2.37 and a beta of 2.25. The company has a current ratio of 5.61, a quick ratio of 5.58 and a debt-to-equity ratio of 0.13.

Affimed (NASDAQ:AFMD) last announced its earnings results on Tuesday, March 20th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). Affimed had a negative net margin of 1,493.69% and a negative return on equity of 80.04%. The firm had revenue of $0.75 million for the quarter, compared to the consensus estimate of $0.56 million. research analysts forecast that Affimed will post -0.65 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC grew its holdings in Affimed by 483.0% during the 4th quarter. Virtu Financial LLC now owns 85,562 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 70,886 shares in the last quarter. Two Sigma Securities LLC acquired a new position in Affimed during the 4th quarter worth approximately $136,000. Dimensional Fund Advisors LP grew its holdings in Affimed by 817.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 137,783 shares of the biopharmaceutical company’s stock worth $310,000 after acquiring an additional 122,773 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Affimed during the 3rd quarter worth approximately $658,000. Institutional investors own 27.86% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Affimed (AFMD) Lowered to Hold at Zacks Investment Research” was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2018/03/31/affimed-afmd-lowered-to-hold-at-zacks-investment-research.html.

Affimed Company Profile

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply